<DOC>
	<DOCNO>NCT01487096</DOCNO>
	<brief_summary>The primary objective study determine safety efficacy teriflunomide multiple sclerosis ( MS ) relapse . Secondary objective : - To determine effect teriflunomide additional magnetic resonance imaging ( MRI ) variables well clinical quality life measure . - To investigate pharmacokinetic pharmacodynamic relationship .</brief_summary>
	<brief_title>Safety Efficacy Teriflunomide ( HMR1726 ) Multiple Sclerosis With Relapses</brief_title>
	<detailed_description>The total duration study period per participant 46 week comprise 3 period : - 4-week screening period , - 36-week double-blind treatment period , - 6-week post-treatment follow-up period . Participants successfully complete double-blind treatment phase offer possibility continue study treatment extension study LTS6048 - NCT00228163 .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>Clinically confirm multiple sclerosis [ MS ] ; Expanded Disability Status Scale [ EDSS ] score less equal 6 ; Two document relapse previous 3 year , one clinical relapse precede year ; Screening magnetic resonance image [ MRI ] scan fulfilling criterion diagnosis MS. Clinically relevant cardiovascular , hepatic , hematologic , neurological , endocrine major systemic disease ; Pregnant nursing woman ; Wish parent child trial follow trial ( men woman require practice effective contraception trial 24 month drug discontinuation ) ; Prior treatment interferon [ IFN ] , gammaglobulin , glatiramer acetate , noncorticosteroid immunomodulatory therapy 4 month prior trial ; Use cladribine , mitoxantrone , immunosuppressant agent azathioprine , cyclophosphamide , cyclosporin , methotrexate mycophenolate enrollment ; Any known condition circumstance would prevent investigator 's opinion compliance completion study . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>